Literature DB >> 24590984

Fibroblast growth factor 21 protects against acetaminophen-induced hepatotoxicity by potentiating peroxisome proliferator-activated receptor coactivator protein-1α-mediated antioxidant capacity in mice.

Dewei Ye1, Yudong Wang, Huating Li, Weiping Jia, Kwan Man, Chung Mau Lo, Yu Wang, Karen S L Lam, Aimin Xu.   

Abstract

UNLABELLED: Acetaminophen (APAP) overdose is a leading cause of drug-induced hepatotoxicity and acute liver failure worldwide, but its pathophysiology remains incompletely understood. Fibroblast growth factor 21 (FGF21) is a hepatocyte-secreted hormone with pleiotropic effects on glucose and lipid metabolism. This study aimed to investigate the pathophysiological role of FGF21 in APAP-induced hepatotoxicity in mice. In response to APAP overdose, both hepatic expression and circulating levels of FGF21 in mice were dramatically increased as early as 3 hours, prior to elevations of the liver injury markers alanine aminotransferase (ALT) and aspartate aminotransferase (AST). APAP overdose-induced liver damage and mortality in FGF21 knockout (KO) mice were markedly aggravated, which was accompanied by increased oxidative stress and impaired antioxidant capacities as compared to wild-type (WT) littermates. By contrast, replenishment of recombinant FGF21 largely reversed APAP-induced hepatic oxidative stress and liver injury in FGF21 KO mice. Mechanistically, FGF21 induced hepatic expression of peroxisome proliferator-activated receptor coactivator protein-1α (PGC-1α), thereby increasing the nuclear abundance of nuclear factor erythroid 2-related factor 2 (Nrf2) and subsequent up-regulation of several antioxidant genes. The beneficial effects of recombinant FGF21 on up-regulation of Nrf2 and antioxidant genes and alleviation of APAP-induced oxidative stress and liver injury were largely abolished by adenovirus-mediated knockdown of hepatic PGC-1α expression, whereas overexpression of PGC-1α was sufficient to counteract the increased susceptibility of FGF21 KO mice to APAP-induced hepatotoxicity.
CONCLUSION: The marked elevation of FGF21 by APAP overdose may represent a compensatory mechanism to protect against the drug-induced hepatotoxicity, by enhancing PGC-1α/Nrf2-mediated antioxidant capacity in the liver.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24590984     DOI: 10.1002/hep.27060

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  68 in total

1.  FGF21 is induced in cisplatin nephrotoxicity to protect against kidney tubular cell injury.

Authors:  Fanghua Li; Zhiwen Liu; Chengyuan Tang; Juan Cai; Zheng Dong
Journal:  FASEB J       Date:  2018-01-22       Impact factor: 5.191

2.  Fibroblast growth factor 21 protects the heart from apoptosis in a diabetic mouse model via extracellular signal-regulated kinase 1/2-dependent signalling pathway.

Authors:  Chi Zhang; Zhifeng Huang; Junlian Gu; Xiaoqing Yan; Xuemian Lu; Shanshan Zhou; Shudong Wang; Minglong Shao; Fangfang Zhang; Peng Cheng; Wenke Feng; Yi Tan; Xiaokun Li
Journal:  Diabetologia       Date:  2015-06-04       Impact factor: 10.122

3.  Loss of FGF21 in diabetic mouse during hepatocellular carcinogenetic transformation.

Authors:  Quan Zhang; Yan Li; Tingting Liang; Xuemian Lu; Xingkai Liu; Chi Zhang; Xin Jiang; Robert C Martin; Mingliang Cheng; Lu Cai
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

4.  Long-Term Administration of Fibroblast Growth Factor 21 Prevents Chemically-Induced Hepatocarcinogenesis in Mice.

Authors:  Pengfei Xu; Yingjie Zhang; Wenfei Wang; Qingyan Yuan; Zhihang Liu; Lubna Muhi Rasoul; Qiang Wu; Mingyao Liu; Xianlong Ye; Deshan Li; Guiping Ren
Journal:  Dig Dis Sci       Date:  2015-05-24       Impact factor: 3.199

Review 5.  Fibroblast growth factor 21 in chronic kidney disease.

Authors:  Paulo Giovanni de Albuquerque Suassuna; Rogério Baumgratz de Paula; Hélady Sanders-Pinheiro; Orson W Moe; Ming-Chang Hu
Journal:  J Nephrol       Date:  2018-11-14       Impact factor: 3.902

Review 6.  Fibroblast growth factors 19 and 21 in acute liver damage.

Authors:  Zhao Shan; Gloria Alvarez-Sola; Iker Uriarte; María Arechederra; Maite G Fernández-Barrena; Carmen Berasain; Cynthia Ju; Matías A Avila
Journal:  Ann Transl Med       Date:  2018-06

7.  Induction of mitochondrial biogenesis protects against acetaminophen hepatotoxicity.

Authors:  Kuo Du; Anup Ramachandran; Mitchell R McGill; Abdellah Mansouri; Tarik Asselah; Anwar Farhood; Benjamin L Woolbright; Wen-Xing Ding; Hartmut Jaeschke
Journal:  Food Chem Toxicol       Date:  2017-08-18       Impact factor: 6.023

8.  Osteocalcin improves nonalcoholic fatty liver disease in mice through activation of Nrf2 and inhibition of JNK.

Authors:  Jing Du; Mingliang Zhang; Junxi Lu; Xueli Zhang; Qin Xiong; Yiting Xu; Yuqian Bao; Weiping Jia
Journal:  Endocrine       Date:  2016-03-19       Impact factor: 3.633

Review 9.  The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic.

Authors:  Leiluo Geng; Karen S L Lam; Aimin Xu
Journal:  Nat Rev Endocrinol       Date:  2020-08-06       Impact factor: 43.330

Review 10.  Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic Diseases.

Authors:  Fangfang Zhang; Lechu Yu; Xiufei Lin; Peng Cheng; Luqing He; Xiaokun Li; Xuemian Lu; Yi Tan; Hong Yang; Lu Cai; Chi Zhang
Journal:  Mol Endocrinol       Date:  2015-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.